scholarly journals Treatment of adult rhabdoid renal cell carcinoma with sorafenib

2008 ◽  
Vol 2 (6) ◽  
pp. 631 ◽  
Author(s):  
Anil Kapoor ◽  
Robert Tutino ◽  
Androniki Kanaroglou ◽  
Sebastien J. Hotte
Keyword(s):  
Renal Cell Carcinoma ◽  
Tyrosine Kinase Inhibitor ◽  
Cell Carcinoma ◽  
Renal Cell ◽  
Kinase Inhibitor ◽  
Clear Cell ◽  
Review Of The Literature ◽  
Histological Findings ◽  
Sorafenib Therapy ◽  
Rhabdoid Features

Renal cell carcinoma (RCC) with rhabdoid features is an uncommon and highly aggressive malignancy. We report a case of adult clear-cell RCC with extensive rhabdoid features treated with the tyrosine kinase inhibitor sorafenib. A review of the literature summarizes important aspects of this malignancy. We discuss clinical and histological findings as well as the patient’s response to sorafenib therapy.

Tyrosine kinase inhibitor-induced vasculopathy in clear cell renal cell carcinoma: an unrecognized antitumour mechanism

2013 ◽  
Vol 64 (4) ◽  
pp. 484-493 ◽  
Author(s):  
Toyonori Tsuzuki ◽  
Naoto Sassa ◽  
Yoshie Shimoyama ◽  
Takamitsu Morikawa ◽  
Ryoichi Shiroki ◽  
...  
Keyword(s):  
Renal Cell Carcinoma ◽  
Tyrosine Kinase ◽  
Tyrosine Kinase Inhibitor ◽  
Cell Carcinoma ◽  
Renal Cell ◽  
Kinase Inhibitor ◽  
Clear Cell ◽  
Cell Renal Cell Carcinoma

scholarly journals Tyrosine Kinase Inhibitor Sorafenib Decreases 111In-Girentuximab Uptake in Patients with Clear Cell Renal Cell Carcinoma

2014 ◽  
Vol 55 (2) ◽  
pp. 242-247 ◽  
Author(s):  
C. H. J. Muselaers ◽  
A. B. Stillebroer ◽  
I. M. E. Desar ◽  
M. J. Boers-Sonderen ◽  
C. M. L. van Herpen ◽  
...  
Keyword(s):  
Renal Cell Carcinoma ◽  
Tyrosine Kinase ◽  
Tyrosine Kinase Inhibitor ◽  
Cell Carcinoma ◽  
Renal Cell ◽  
Kinase Inhibitor ◽  
Clear Cell ◽  
Cell Renal Cell Carcinoma

scholarly journals Targeted Therapy for Renal Cell Carcinoma: a Prospective study

2015 ◽  
Vol 53 (198) ◽  
pp. 83-88
Author(s):  
Robin Joshi ◽  
Sudhir Rawal
Keyword(s):  
Renal Cell Carcinoma ◽  
Targeted Therapy ◽  
Prospective Study ◽  
Tyrosine Kinase Inhibitor ◽  
Cell Carcinoma ◽  
Metastatic Renal Cell Carcinoma ◽  
Renal Cell ◽  
Kinase Inhibitor ◽  
Clear Cell ◽  
A Prospective Study

Introduction: Our study aims to evaluate the use of targeted therapy in metastatic renal cell carcinoma. Methods: This is a prospective study done over three years from December 2010 to December, 2013. Out of Forty seven patients of metastatic renal cell carcinoma 8(neo-adjuvant cases) were excluded and 39 were included in this study. All patients received Tyrosine kinase inhibitor, sunitinib therapy (50 mg OD, 4/2 scheme). All 39 patients underwent radical nephrectomy prior to sunitinib therapy. Patients were followed up every cycle for their clinical symptoms following sunitinib therapy and every 3 months with chest X-ray, ultra-sonography and bone scan. CT scan was done if needed. A RECIST criterion was used to evaluate the complete, partial and no tumor response. Results: The median survival was 28.5 months (CI 9.253-47.7) and progression free survival (PFS) was 9.16 months(CI 6.08-12.23).According to RECIST, stable disease was found in 6 patients till date and a complete response in two patients. Clear cell histology was found in 30(76.9%) patients, papillary variety in 6(15.39%) patients, chromophobe type was seen in one patient and rest had mixed sarcomatoid papillary and rhabdoid clear cell variety. Twenty four patients (61.5%) had multiple metastases. Most frequent metastasis was seen in lungs in 14 patients (36%) and bone in 12 patients (31%).Metastases were also seen in draining lymph nodes, adrenals, omentum,skin, liver, and brain. Conclusions: In our cohort, use of sunitinib showed similar outcome to previously published articles. Our study supports the use of sunitinib in metastatic renal cell carcinoma.  Keywords: metastatic renal cell carcinoma; sunitinib; tyrosine kinase inhibitor.

scholarly journals MiR-99b-5p expression and response to tyrosine kinase inhibitor treatment in clear cell renal cell carcinoma patients

Oncotarget ◽  
2016 ◽  
Vol 7 (48) ◽  
pp. 78433-78447 ◽  
Author(s):  
Magdalena Lukamowicz-Rajska ◽  
Christiane Mittmann ◽  
Michael Prummer ◽  
Qing Zhong ◽  
Jens Bedke ◽  
...  
Keyword(s):  
Renal Cell Carcinoma ◽  
Tyrosine Kinase ◽  
Tyrosine Kinase Inhibitor ◽  
Cell Carcinoma ◽  
Renal Cell ◽  
Kinase Inhibitor ◽  
Clear Cell ◽  
Cell Renal Cell Carcinoma ◽  
Inhibitor Treatment
Sign in / Sign up

Export Citation Format

Share Document